This type of ADEV model is not uncommon in US academic departments. The milestones declared by FibrosIX are (by implication) guidelines and commercialisation plans proposed by two leading academic pharmacologists. These include;  Anti-fibrotic efficacy in TSK-1 mice,  Salt selection based on physical properties  In vitro ADME profiling  Oral PK in mice  14-day multiple dose tolerance in mice,  Anti-fibrotic efficacy in bleomycin-treated mice at three doses  Oral PK in rats  Non-GLP tox in rats  Anti-fibrotic efficacy in TSK-1 mice.  Application for Orphan Drug Status and Fast Track Designation  Licencing or acquisition opportunities Continuing the analysis of compounds implicitly associated with FibrosIX we can find a lot of information associated with 3971 in PubChem CID 71681561. For example, it indexes isomers of 3971 not mentioned in the paper. However, the R and S isomers in this case are virtual enumerations from the vendor aggregator (ZINC15) so their status as pharmacologically-relevant entities is unclear. The Nuebig team recently published a target deconvolution paper (see 'Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds', 2019, Doi/10.1021/acsptsci.8b00048). The informatics gotcha here is that the paper cannot currently be found in PubMed because, as a new journal, ACS Pharmacol. Transl. Sci. is PubMed indexed only for two open access papers. Notwithstanding, the report declares an n2s for the FibrosIX lead compound CGC-257081 which maps to PubChem CID 121317995 but only the structure (i.e. not a n2s). Unsurprisingly, along with CCG-203971, SureChEMBL establishes this also originated from WO2016073847 as example 41. What was surprising was the Google findability of CGC-257081 n2s as a vendor listing (but, not unexpectedly, offered via custom synthesis as opposed to a stock item).